Insulet Full Year 2023 Earnings: Beats Expectations
Insulet (NASDAQ:PODD) Full Year 2023 Results
Key Financial Results
Revenue: US$1.70b (up 30% from FY 2022).
Net income: US$206.3m (up by US$201.7m from FY 2022).
Profit margin: 12% (up from 0.4% in FY 2022). The increase in margin was driven by higher revenue.
EPS: US$2.96 (up from US$0.066 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Insulet Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 48%.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 3.6% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Insulet has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
